arrow
C

Claudio Vernieri

Marche Polytechnic University
H指数:35
被引数:4,451

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Broad baseline-variable profiling of visceral conversion in bone-only HR+/ HER2-metastatic breast cancer treated with CDK4/6 inhibitors

骨转移性HR+/HER2-转移性乳腺癌经CDK4/6抑制剂治疗后腹腔转化的大范围基线-变量分析

2026-09-011
OA
De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+breast cancer: An international real-world study.

年轻女性中I期HR+/HER2+乳腺癌降级化疗和内分泌治疗效果:一项国际真实世界研究

2026-06-010
PRE
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer

BRCA突变HR阳性/HER2阴性晚期乳腺癌在接受CDK4/6抑制剂治疗后使用PARP抑制剂的实效性

2025-12-130
OAAI
Fasting boosts breast cancer therapy efficacy via glucocorticoid activation

禁食通过糖皮质激素激活增强乳腺癌治疗效果

Nature
IF48.5
2025-12-100
OAAI
Sentinel Node Biopsy Alone Versus Sentinel Node Biopsy Plus Axillary Dissection in cT2 cN0/1 Breast Cancer After Neoadjuvant Chemotherapy: 15-Year Results of a Prospective Interventional Study

cT2 cN0/1乳腺癌新辅助化疗后,仅行哨兵淋巴结活检与哨兵淋巴结活检联合腋窝清扫的比较:一项前瞻性干预研究的15年结果

2025-11-180
PRE
Health-related quality of life and fear of recurrence after early breast cancer treatment: results from a cross-sectional survey

健康相关生活质量及治疗后复发恐惧:一项横断面调查的结果

2025-11-130
OAAI
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysis

HR+/HER2−转移性乳腺癌患者在CDK4/6抑制剂进展后接受全身治疗的疗效与安全性:一项系统评价和网络荟萃分析

2025-09-300
OAAI
Prognostic significance of tumour Ki-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort study

乳腺癌患者新辅助治疗期间肿瘤Ki-67动态变化的预后意义:一项基于人群的队列研究

2025-09-020
PREAI
Breastfeeding after breast cancer in young BRCA carriers

Blondeaux, E.; Delucchi, V.; Mariamidze, E.; Bernstein-Molho, R.; Frank, S.; Ferrari, A.; Linn, S.; Jeong Kim, H.; Agostinetto, E.; Paluch-Shimon, S.; 等. 乳腺癌后母乳喂养在年轻BRCA携带者中的应用. J. Natl. Cancer Inst. 2025, djaf177. [Google Scholar] [CrossRef] [PubMed]

2025-08-012
OAAI
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study

风险降低手术与年轻BRCA携带者乳腺癌患者生存期的关联:一项国际队列研究

2025-05-080
PRE
Antitumor immunological benefits of Vitamin E analogue δ-tocotrienol in early breast cancer patients depend on body mass index: results from the TOCANNATO window-of-opportunity trial

维生素E类似物δ-tocotrienol在早期乳腺癌患者中的抗肿瘤免疫益处取决于体重指数:TOCANNATO窗口期机会试验的结果

BREAST
IF7.9
2025-02-010
OAAI
CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer

CD36富集在HER2阳性间充质干细胞中,驱动乳腺癌的治疗抵抗性

2025-01-201
OA
Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology
2024-10-010
OAAI
Impact of hormone receptor status and tumor subtypes of breast cancer in young BRCA carriers
2024-09-012
OAAI
Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study Editoral Comment
2024-08-010
OA
International consensus on fasting terminology
2024-08-017
OAAI
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer

雌激素受体低和阴性早期乳腺癌的免疫和基因表达谱

2024-07-312
OAAI